We confirmed that miR‐484 serves not only as a potential indicator for the early screening and assessment of DN but also as a therapeutic candidate that improves glucose metabolism and protects renal function by inhibiting SGLT2 expression. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.